Stifel reiterates Hold on ResMed stock amid market share concerns
Stifel maintained a Hold rating on ResMed (RMD) with a $235 price target, citing potential market share pressures. The firm expects RMD's U.S. device market share to decline to 75% if Philips reenters. RMD's Q4 earnings beat EPS estimates but missed on revenue. RBC and KeyBanc raised price targets, while Rothschild initiated with a Neutral rating.
How this was made
The 30-second read
Why it matters
Analyst consensus remains positive but cautious, keeping the stock in a hold position.
Market read
The note provides modest guidance for investors but lacks a new catalyst, resulting in limited trading relevance.
What to watch
Upcoming regulatory changes for CPAP devices and macro‑economic headwinds could affect demand.
Background
Stifel's research note follows ResMed's recent Q4 earnings that beat EPS estimates but missed revenue, and follows upgrades from RBC, KeyBanc, and Rothschild Redburn.
Ticker impact
Stifel reiterated a Hold rating on ResMed with a $235 price target, citing market‑share pressure from a possible competitor re‑entry.
likely limited pressure as the market prices in the hold stance and modest target uplift.
The rating is unchanged and the target increase is small; investors may hold positions but no strong catalyst for a move.
Market effects
Potential competitive pressure in the sleep‑apnea device market if Philips re‑enters.
U.S. market only; no broader regional effect.
Limited to the medical device sector.
Counterpoint
If Philips re‑enters aggressively, ResMed could lose share and the hold rating may become a sell.
Key entities
- Research FirmStifel
Issued the Hold rating and $235 price target.
- CompanyResMed Inc.
Medical device maker for sleep‑apnea equipment.
